Integrating the models of PAR2 function in the vasculature with its concomitant actions elsewhere, which promote obesity, is a logical step toward a better understanding of the balance of PAR2 therapeutics for metabolic dysfunction and cardiovascular risk. Here, F2RL1 is linked to obesity due to melanocortin 4 receptor deficiency.